Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30230436 | 0.86 | GRM5 (0.32) | GRM5ACACB | |
| SCHEMBL18664061 | 0.84 | ACACB (0.46) | GRM5ACACBHAO1BRD4BRD2 | |
| SCHEMBL18664116 | 0.80 | ACACB (0.41) | GRM5ACACBHAO1BRD4BRD2 | |
| SCHEMBL13306665 | 0.78 | — | — | |
| SCHEMBL31086959 | 0.77 | MTOR (0.37) | GRM5CYP11B1CYP11B2 | |
| SCHEMBL20642235 | 0.77 | — | — | |
| SCHEMBL25362235 | 0.76 | L3MBTL1 (0.44) | — | |
| SCHEMBL28521746 | 0.76 | CHRNB2 (0.34) | — | |
| SCHEMBL12491679 | 0.75 | ACHE (0.31) | — | |
| SCHEMBL15904517 | 0.75 | KMT2A (0.35) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070911-A1 | INHIBITORS OF TAM RECEPTORS | NATIONAL HEALTH RES INST (TW) | 2026-03-12 | — | — | US | disclosed |
| EP-4688778-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Biogen MA Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| CN-119968372-A | TAM receptor inhibitors | 台湾卫生研究院 | 2025-05-09 | — | — | CN | disclosed |
| CN-115873000-B | Isoquinolinones and quinazolinones compounds, and composition and application thereof | 中山医诺维申新药研发有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024211696-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| CN-117964643-B | Pyrrole [2,3-b ] pyridine derivative and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117964643-A | Pyrrole [2,3-b ] pyridine derivative and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-11939333-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | INFINITY PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11939333-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | INFINITY PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2014022128-A1 | PI3 KINASE MODULATORS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2014-02-06 | — | — | WO | disclosed |
| EP-2686318-A1 | PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS | Cancer Research Technology Ltd (GB) | 2014-01-22 | — | — | EP | disclosed |
| CN-103517903-A | Pyrrolopyridineamino derivatives as MPS1 inhibitors | CANCER REC TECH LTD | 2014-01-15 | — | — | CN | disclosed |
| CN-102711470-A | Novel tricyclic compounds | ABBOTT LAB | 2012-10-03 | — | — | CN | disclosed |
| WO-2012123745-A1 | PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-09-20 | — | — | WO | disclosed |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
| US-20100124550-A1 | AMIDE INHIBITORS OF RENIN | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100124550-A1 | AMIDE INHIBITORS OF RENIN | REN, ACE, AGTR2 | GRM5 1265/4885ACACB 345/4885HAO1 1401/4885 |
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | HTR2A, HTR2C, HTR2B | GRM5 39/4885ACACB 3940/4885HAO1 1437/4885 |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ABL1, ERBB2, RET | GRM5 806/4885ACACB 3158/4885HAO1 3532/4885 |
| US-11939333-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | PIK3CA, PIK3C2A, PIK3CD | GRM5 4343/4885ACACB 792/4885HAO1 2260/4885 |
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | GRM5 1627/4885ACACB 1826/4885HAO1 999/4885 |
| US-20260070911-A1 | INHIBITORS OF TAM RECEPTORS | CNR1, MSR1, HCAR1 | GRM5 610/4885ACACB 3264/4885HAO1 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.